EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY 4.0

Effect of Hepatic and Renal Impairment on the Pharmacokinetics of Dersimelagon (MT‐7117), an Oral Melanocortin‐1 Receptor Agonist

Akihito Ogasawara, Ryosuke Ide, Shinsuke Inoue, Renli Teng, Atsuhiro Kawaguchi

Clinical Pharmacology in Drug Development · 2024

DOI: 10.1002/cpdd.1413 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical Pharmacology in Drug Development, 2024. Verfasst von Akihito Ogasawara und 4 weiteren Autor:innen. Beteiligte Einrichtung: Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan. Hauptthemen laut MEDLINE: Receptor, Melanocortin, Type 1. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Mitsubishi Tanabe Pharma Corporation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dersimelagon is an orally administered selective melanocortin‐1 receptor agonist being investigated for treatment of erythropoietic protoporphyria, X‐linked protoporphyria, and diffuse cutaneous systemic sclerosis. Dersimelagon is extensively metabolized in the liver, and potential recipients may have liver dysfunction. Further, effects of renal impairment on pharmacokinetic properties should be established in drugs intended for chronic use. Two separate studies (ClinicalTrials.gov: NCT04116476; NCT04656795) evaluated the effects of hepatic and renal impairment on dersimelagon pharmacokinetics, safety, and tolerability. Participants with mild (n = 7) or moderate (n = 8) hepatic impairment or normal hepatic function (n = 8) received a single oral 100‐mg dersimelagon dose. Participants with mild (n = 8), moderate (n = 8), or severe (n = 8) renal impairment or normal renal function (n = 8) received a single 300‐mg dose. Systemic exposure to dersimelagon was comparable with mild hepatic impairment but higher with moderate hepatic impairment (maximum observed plasma concentration, 1.56‐fold higher; area under the plasma concentration‐time curve from time 0 extrapolated to infinity, 1.70‐fold higher) compared with normal hepatic function. Maximum observed plasma concentration and area under the plasma concentration‐time curve from time 0 extrapolated to infinity were similar with moderate renal impairment but higher with mild (1.86‐ and 1.87‐fold higher, respectively) and severe (1.17‐ and 1.45‐fold higher, respectively) renal impairment versus normal renal function. Dersimelagon was generally well tolerated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptor, Melanocortin, Type 1HumansMaleFemaleMiddle AgedAdultAdministration, OralAgedLiver DiseasesArea Under CurveRenal InsufficiencyYoung Adultalpha-MSHSeverity of Illness Index

Stichwörter der Autor:innen

dersimelagonerythropoietic protoporphyriahepatic impairmentrenal impairment

Substanzen

Receptor, Melanocortin, Type 1alpha-MSHMC1R protein, human

Autor:innen und Institutionen

  • Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan.
  • Mitsubishi Tanabe Pharma Development America, Inc., Jersey City, NJ, USA.
  • CareCeutics LLC, Berwyn, Pennsylvania, USA.

Förderung

  • Mitsubishi Tanabe Pharma Corporation

Zitieren

APA

Ogasawara, A., Ide, R., Inoue, S., Teng, R., & Kawaguchi, A. (2024). Effect of Hepatic and Renal Impairment on the Pharmacokinetics of Dersimelagon (MT‐7117), an Oral Melanocortin‐1 Receptor Agonist. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1413

Vancouver

Ogasawara A, Ide R, Inoue S, Teng R, Kawaguchi A. Effect of Hepatic and Renal Impairment on the Pharmacokinetics of Dersimelagon (MT‐7117), an Oral Melanocortin‐1 Receptor Agonist. Clinical Pharmacology in Drug Development. 2024. doi:10.1002/cpdd.1413

BibTeX
@article{Ogasawara2024,
  author = {Ogasawara, Akihito and Ide, Ryosuke and Inoue, Shinsuke and Teng, Renli and Kawaguchi, Atsuhiro},
  title = {Effect of Hepatic and Renal Impairment on the Pharmacokinetics of Dersimelagon (MT‐7117), an Oral Melanocortin‐1 Receptor Agonist},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2024},
  doi = {10.1002/cpdd.1413}
}
Kostenlos starten →